The products listed below are in various stages of research and development. To better understand their status, a brief description of clinical trial stages is available. In addition, don't miss The Pharmaceutical Pipeline, an innovative and enjoyable program for learning about the challenges of drug discovery and development.
| Eplerenone
|
A potential extension to Searle's established line of anti-aldosterone
agents. Elevated levels of the hormone aldosterone are associated with
high blood pressure, congestive heart failure and complications of
kidney disease. It is believed that eplerenone may cause fewer side
effects than similar, existing drugs.
|
| Tissue Factor Pathway Inhibitor (TFPI)
|
A genetically engineered protein that blocks biochemical
processes in the body that lead to blood clotting, inflammation and
cell proliferation. TFPI is currently being tested in humans for the
treatment of sepsis, a potentially life-threatening condition
resulting from severe infection of the blood.
|
| Xemilofiban
|
An orally active anti-platelet agent (GPIIb/IIIa receptor antagonist) designed
for acute/short-term use in preventing thrombotic complications (blood-clot
formation) following percutaneous coronary angioplasty (a surgical treatment
for clearing blocked arteries).
|
| Orbofiban Acetate
|
An orally active anti-platelet agent (GPIIb/IIIa receptor antagonist) designed
for long-term use in treating unstable angina (chest pain) and prevention of
second thrombotic events (blood-clot formation).
|
|
Daniplestim
|
An interleukin-3 (IL-3) receptor agonist designed to stimulate bone marrow to produce and release early-stage, or "precursor," blood cells. The drug is intended to help prepare patients for peripheral blood stem cell transplantation
following very high-dose chemotherapy.
|
|
Myelopoietin (MPO)
|
A second-generation stimulator of blood-cell growth that interacts with receptors for both interleukin-3 and granulocyte colony
stimulating factor (G-CSF). MPO combines into one molecule the benefits of an early-acting growth factor (daniplestim) with a
late-acting neutrophil growth factor. The unique mechanism of action of MPO is expected to result in greater replenishment of neutrophils
(mature white blood cells) following chemotherapy, the key to preventing infections in cancer patients.
|
|
Celecoxib
|
Celecoxib is a member of a new class of drugs known as specific COX-2
inhibitors. Celecoxib is currently being evaluated in Phase III
clinical trials to determine if it is effective in the treatment of
arthritis without causing damage to the stomach, intestine or kidney.
|
Next stop on the guided tour is the products on the market page. Or, choose another section to visit:
 |
 |
 |
 |  |
 |
 |
 |
